Harry Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Richard L. Cassin Editor at Large

Elizabeth K. Spahn Editor Emeritus 

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor

FCPA Blog Daily News

« Whistleblowing cardiologist collects $6 million from FCA settlement | Main | Priscila Akemi Beltrame: More Brazil agencies require mandatory compliance programs »

Sanofi discloses DOJ declination in FCPA investigation

French pharma Sanofi said Wednesday the DOJ has closed an FCPA investigation that started four years ago.

The company said it heard from the DOJ in February.

But Sanofi said it is still cooperating with the SEC’s "review of the allegations."

Sanofi disclosed in 2014 an investigation into possible illegal payments in the Middle East and Africa from 2007 to 2012, following allegations from an anonymous whistleblower.

The company self reported the allegations to the DOJ and SEC.

It hired New York law firm Weil Gotshal for the investigation.

*     *     *

Here's the full FCPA disclosure from Sanofi's March 7, 2018 Form 20-F filed with the SEC (courtesy of FCPA Tracker):

Sanofi has been engaged in discussions with the US Department of Justice (“DOJ”) and the US Securities and Exchange Commission regarding allegations that certain subsidiaries outside the United States made improper payments in connection with the sale of pharmaceutical products and whether those payments, if made, fall within the U.S. Foreign Corrupt Practices Act. Sanofi has voluntarily provided information to the DOJ and the SEC and proactively cooperated in both agencies’ review of the allegations. In February 2018, the DOJ notified Sanofi that it had decided to close its inquiry into the allegations. Sanofi is still cooperating with the SEC’s review of the allegations.


Richard L. Cassin is the publisher and editor of the FCPA Blog.